The Cannabinoid Institute Offers Medical Cannabis Training Courses Free of Charge
NEW YORK – The Cannabinoid Institute (TCI) announced that it is offering its cannabis training certification courses free of charge to 100 medical students in the state of New York. Courses will be awarded to the first 100 applicants who supply proof of their status as enrolled NY state medical students at [email protected].
With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. Since less than 10% of medical schools teach about the endocannabinoid system and cannabis from a scientific and objective lens, TCI is offering its courses free of charge to medical students since they represent the next generation of physicians who will benefit from understanding the complexities of the endocannabinoid system and medical cannabis and in order to meet the needs of patients who are increasingly looking to plant-based alternatives as part of their treatment plans. Medical students who register for the program will have access to eight hours of medical cannabis education, including the latest scientific research on the endocannabinoid system and the known effects of cannabis on the human body. This certification course is also offered to practicing physicians who are eligible to receive ACCME tier-1 credit. In order to offer its courses more widely, TCI is in discussion with additional potential underwriters of its courses to provide students across healthcare disciplines with the education they need to meet the changing landscape concurrent with the legalization of cannabis.
TCI was founded by Drs. Jan Roberts and Stacia Woodcock with the objective of reducing adverse reactions for patients and ensuring clinicians can provide their patients with the most knowledgeable guidance available. With patient safety at the center of its mission, TCI was created to educate healthcare professionals on the risks and benefits of medical cannabis, now legal in the state of New York and beyond. Historically treated as a Schedule I drug which prevented medical cannabis research for the past 50 years, TCI’s certification courses teach the science of the body’s endocannabinoid system, medicinal uses of the plant, and the potential risks and benefits of cannabis use, including drug to drug interactions, among other topics.
“When I conducted my academic research on clinicians’ knowledge and attitudes on medical cannabis, it became apparent many clinicians had not heard of the endocannabinoid system or how different methods of consumption and dosing impacted patients and their outcomes. The data revealed that clinicians who had never experienced cannabis firsthand viewed it much more negatively and stigmatized, whereas clinicians who had experience firsthand with cannabis understood the potential medical benefit for some clinical conditions,” noted Jan Roberts, Founder of TCI. “Our concern for patient safety and creating positive outcomes has informed TCI’s goal to arm healthcare professionals with the latest information on the endocannabinoid system and medical cannabis. We are delighted to be able to offer certification courses to NY state medical students who will be on the front line of patient care as medicinal cannabis research unlocks potential treatment options.”
(This information is primarily sourced from The Cannabinoid Institute. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Innocan Pharma Reports Significant Revenue Growth and Impressive Gross Profit in Q1 2023
LOS ANGELES-- Innocan Pharma Corporation, a pharmaceutical technology company specializing in innovative drug delivery platform technologies, has announced its financial results for the first quarter ended March 31, 2023. The company reported significant growth in ...
Minnesota Legalizes Adult-Use or Recreational Cannabis
ST PAUL, MN–Minnesota Governor Tim Walz, a Democrat, made a significant move on Tuesday by signing a bill that legalizes the recreational use of cannabis in the state. With this signature, Minnesota becomes the 23rd ...
Canopy Growth Acquires 19.99% Stake in Indiva, Secures Distribution Rights for Wana Edibles in Canada
LOS ANGELES-- In a strategic move to expand its presence in the cannabis edibles market, Canadian cannabis producer Canopy Growth has announced the acquisition of a 19.99% stake in edibles manufacturer Indiva. The deal also ...